The Regulation of Multiple p53 Stress Responses is Mediated through MDM2

Genes and Cancer

Volumn 3, Issue 3-4, 2012, Pages 199-208

  Hu, Wenwei ^a   Feng, Zhaohui ^a   Levine, Arnold J ^b  

^a RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^b INSTITUTE FOR ADVANCED STUDY   (United States)

Author keywords

MDM2; p53; stress; ubiquitination

Indexed keywords

ADRENALIN; ARF PROTEIN; ATM PROTEIN; ATR PROTEIN; CYCLIN A; GLUCOCORTICOID; MESSENGER RNA; MICRORNA; NEUROHORMONE; PROTEIN KINASE B; PROTEIN MDM2; PROTEIN P53; RIBOSOME RNA;

CARCINOGENESIS; CELL CYCLE REGULATION; CELLULAR DISTRIBUTION; CELLULAR STRESS RESPONSE; CHRONIC STRESS; DNA DAMAGE; GENE ACTIVATION; HUMAN; IONIZING RADIATION; MALIGNANT TRANSFORMATION; NEGATIVE FEEDBACK; NONHUMAN; ONCOGENE; ONCOGENE MDM2; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REVIEW; RIBOSOME; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE; ULTRAVIOLET RADIATION;

EID: 84872776313     PISSN: 19476019     EISSN: 19476027     Source Type: Journal    
DOI: 10.1177/1947601912454734     Document Type: Review

References (114)

1. Fakharzadeh SS,Trusko SP,George DL.Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line.EMBO J. 1991;10:1565-9.
2. Momand J,Jung D,Wilczynski S,Niland J.The MDM2 gene amplification database.Nucleic Acids Res. 1998;26:3453-9.
3. Bond GL,Hu W,Bond EE, et al.A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans.Cell. 2004;119:591-602.
4. Thut CJ,Goodrich JA,Tjian R.Repression of p53-mediated transcription by MDM2: a dual mechanism.Genes Dev. 1997;11:1974-86.
5. Grossman SR,Perez M,Kung AL, et al.p300/MDM2 complexes participate in MDM2-mediated p53 degradation.Mol Cell. 1998;2:405-15.
6. Grossman SR,Deato ME,Brignone C, et al.Polyubiquitination of p53 by a ubiquitin ligase activity of p300.Science. 2003;300:342-4.
7. Midgley CA,Desterro JM,Saville MK, et al.An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo.Oncogene. 2000;19:2312-23.
8. Girnita L,Girnita A,Larsson O.Mdm2-dependent ubiquitination and degradation of the insulin-like growth factor 1 receptor.Proc Natl Acad Sci U S A. 2003;100:8247-52.
9. Jin Y,Zeng SX,Lee H,Lu H.MDM2 mediates p300/CREB-binding protein-associated factor ubiquitination and degradation.J Biol Chem. 2004;279:20035-43.
10. Shenoy SK,McDonald PH,Kohout TA,Lefkowitz RJ.Regulation of receptor fate by ubiquitination of activated beta 2-adrenergic receptor and beta-arrestin.Science. 2001;294:1307-13.
11. Sczaniecka M,Gladstone K,Pettersson S,McLaren L,Huart AS,Wallace M.MDM2-mediated ubiquitination of NUMB: identification of a 2nd physiological substrate of MDM2 that employs a dual-site docking mechanism.J Biol Chem. 2012;287:14052-68.
12. Zhu Y,Poyurovsky MV,Li Y, et al.Ribosomal protein S7 is both a regulator and a substrate of MDM2.Mol Cell. 2009;35:316-26.
13. Roth J,Dobbelstein M,Freedman DA,Shenk T,Levine AJ.Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein.EMBO J. 1998;17:554-64.
14. Momand J,Zambetti GP,Olson DC,George D,Levine AJ.The Mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation.Cell. 1992;69:1237-45.
15. Chen J,Marechal V,Levine AJ.Mapping of the p53 and Mdm-2 interaction domains.Mol Cell Biol. 1993;13:4107-14.
16. Oliner JD,Pietenpol JA,Thiagalingam S,Gyuris J,Kinzler KW,Vogelstein B.Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53.Nature. 1993;362:857-60.
17. Montes de Oca Luna R,Wagner DS,Lozano G.Rescue of early embryonic lethality in Mdm2-deficient mice by deletion of p53.Nature. 1995;378:203-6.
18. Sharp DA,Kratowicz SA,Sank MJ,George DL.Stabilization of the MDM2 oncoprotein by interaction with the structurally related MDMX protein.J Biol Chem. 1999;274:38189-96.
19. Gu J,Kawai H,Nie L, et al.Mutual dependence of MDM2 and MDMX in their functional inactivation of p53.J Biol Chem. 2002;277:19251-4.
20. Kawai H,Lopez-Pajares V,Kim MM,Wiederschain D,Yuan ZM.RING domain-mediated interaction is a requirement for MDM2's E3 ligase activity.Cancer Res. 2007;67:6026-30.
21. Jackson MW,Lindstrom MS,Berberich SJ.MdmX binding to ARF affects Mdm2 protein stability and p53 transactivation.J Biol Chem. 2001;276:25336-41.
22. Barboza JA,Iwakuma T,Terzian T,El-Naggar AK,Lozano G.Mdm2 and Mdm4 loss regulates distinct p53 activities.Mol Cancer Res. 2008;6:947-54.
23. Toledo F,Wahl GM.Regulating the p53 pathway: in vitro hypotheses, in vivo veritas.Nat Rev Cancer. 2006;6:909-23.
24. Terzian T,Wang Y,Van Pelt CS,Box NF,Travis EL,Lozano G.Haploinsufficiency of Mdm2 and Mdm4 in tumorigenesis and development.Mol Cell Biol. 2007;27:5479-85.
25. Perry ME,Piette J,Zawadzki JA,Harvey D,Levine AJ.The mdm-2 gene is induced in response to UV light in a p53-dependent manner.Proc Natl Acad Sci U S A. 1993;90:11623-7.
26. Wu X,Bayle JH,Olson D,Levine AJ.The p53-Mdm-2 autoregulatory feedback loop.Genes Dev. 1993;7:1126-32.
27. Barak Y,Juven T,Haffner R,Oren M.Mdm2 expression is induced by wild type p53 activity.EMBO J. 1993;12:461-8.
28. Maya R,Balass M,Kim ST, et al.ATM-dependent phosphorylation of Mdm2 on serine 395: role in p53 activation by DNA damage.Genes Dev. 2001;15:1067-77.
29. Cheng Q,Chen L,Li Z,Lane WS,Chen J.ATM activates p53 by regulating MDM2 oligomerization and E3 processivity.EMBO J. 2009;28:3857-67.
30. Lohrum MA,Ashcroft M,Kubbutat MH,Vousden KH.Identification of a cryptic nucleolar-localization signal in MDM2.Nat Cell Biol. 2000;2:179-81.
31. Weber JD,Taylor LJ,Roussel MF,Sherr CJ,Bar-Sagi D.Nucleolar Arf sequesters Mdm2 and activates p53.Nat Cell Biol. 1999;1:20-6.
32. Gajjar M,Candeias MM,Malbert-Colas L, et al.The p53 mRNA-Mdm2 interaction controls Mdm2 nuclear trafficking and is required for p53 activation following DNA damage.Cancer Cell. 2012;21:25-35.
33. Goldberg Z,Vogt Sionov R,Berger M, et al.Tyrosine phosphorylation of Mdm2 by c-Abl: implications for p53 regulation.EMBO J. 2002;21:3715-27.
34. Meulmeester E,Maurice MM,Boutell C, et al.Loss of HAUSP-mediated deubiquitination contributes to DNA damage-induced destabilization of Hdmx and Hdm2.Mol Cell. 2005;18:565-76.
35. Khoronenkova SV,Dianova II,Ternette N,Kessler BM,Parsons JL,Dianov GL.ATM-dependent downregulation of USP7/HAUSP by PPM1G activates p53 response to DNA damage.Mol Cell. 2012;45:801-13.
36. Tibbetts RS,Brumbaugh KM,Williams JM, et al.A role for ATR in the DNA damage-induced phosphorylation of p53.Genes Dev. 1999;13:152-7.
37. Shinozaki T,Nota A,Taya Y,Okamoto K.Functional role of Mdm2 phosphorylation by ATR in attenuation of p53 nuclear export.Oncogene. 2003;22:8870-80.
38. Lev Bar-Or R,Maya R,Segel LA,Alon U,Levine AJ,Oren M.Generation of oscillations by the p53-Mdm2 feedback loop: a theoretical and experimental study.Proc Natl Acad Sci U S A. 2000;97:11250-5.
39. Lahav G,Rosenfeld N,Sigal A, et al.Dynamics of the p53-Mdm2 feedback loop in individual cells.Nat Genet. 2004;36:147-50.
40. Lu X,Ma O,Nguyen TA,Jones SN,Oren M,Donehower LA.The Wip1 phosphatase acts as a gatekeeper in the p53-Mdm2 autoregulatory loop.Cancer Cell. 2007;12:342-54.
41. Quelle DE,Zindy F,Ashmun RA,Sherr CJ.Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest.Cell. 1995;83:993-1000.
42. Zhu JW,DeRyckere D,Li FX,Wan YY,DeGregori J.A role for E2F1 in the induction of ARF, p53, and apoptosis during thymic negative selection.Cell Growth Differ. 1999;10:829-38.
43. Damalas A,Kahan S,Shtutman M,Ben-Ze'ev A,Oren M.Deregulated beta-catenin induces a p53- and ARF-dependent growth arrest and cooperates with Ras in transformation.EMBO J. 2001;20:4912-22.
44. Korgaonkar C,Hagen J,Tompkins V, et al.Nucleophosmin (B23) targets ARF to nucleoli and inhibits its function.Mol Cell Biol. 2005;25:1258-71.
45. Brady SN,Yu Y,Maggi LB,Weber JD.ARF impedes NPM/B23 shuttling in an Mdm2-sensitive tumor suppressor pathway.Mol Cell Biol. 2004;24:9327-38.
46. Moulin S,Llanos S,Kim SH,Peters G.Binding to nucleophosmin determines the localization of human and chicken ARF but not its impact on p53.Oncogene. 2008;27:2382-9.
47. Chen D,Shan J,Zhu WG,Qin J,Gu W.Transcription-independent ARF regulation in oncogenic stress-mediated p53 responses.Nature. 2010;464:624-7.
48. Zhang Y,Xiong Y.Mutations in human ARF exon 2 disrupt its nucleolar localization and impair its ability to block nuclear export of MDM2 and p53.Mol Cell. 1999;3:579-91.
49. Sherr CJ.Divorcing ARF and p53: an unsettled case.Nat Rev Cancer. 2006;6:663-73.
50. Scheid MP,Marignani PA,Woodgett JR.Multiple phosphoinositide 3-kinase-dependent steps in activation of protein kinase B.Mol Cell Biol. 2002;22:6247-60.
51. Bayascas JR,Alessi DR.Regulation of Akt/PKB Ser473 phosphorylation.Mol Cell. 2005;18:143-5.
52. Sarbassov DD,Guertin DA,Ali SM,Sabatini DM.Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex.Science. 2005;307:1098-101.
53. Zhou BP,Liao Y,Xia W,Zou Y,Spohn B,Hung MC.HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation.Nat Cell Biol. 2001;3:973-82.
54. Lill NL,Grossman SR,Ginsberg D,DeCaprio J,Livingston DM.Binding and modulation of p53 by p300/CBP coactivators.Nature. 1997;387:823-7.
55. Stambolic V,MacPherson D,Sas D, et al.Regulation of PTEN transcription by p53.Mol Cell. 2001;8:317-25.
56. Yang H,Wen YY,Zhao R, et al.DNA damage-induced protein 14-3-3 sigma inhibits protein kinase B/Akt activation and suppresses Akt-activated cancer.Cancer Res. 2006;66:3096-105.
57. Min SH,Kim DM,Heo YS, et al.New p53 target, phosphatase of regenerating liver 1 (PRL-1) downregulates p53.Oncogene. 2009;28:545-54.
58. Vivanco I,Sawyers CL.The phosphatidylinositol 3-kinase AKT pathway in human cancer.Nat Rev Cancer. 2002;2:489-501.
59. Wu X,Senechal K,Neshat MS,Whang YE,Sawyers CL.The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway.Proc Natl Acad Sci U S A. 1998;95:15587-91.
60. Scheid MP,Woodgett JR.PKB/AKT: functional insights from genetic models.Nat Rev Mol Cell Biol. 2001;2:760-8.
61. Zhang T,Prives C.Cyclin a-CDK phosphorylation regulates MDM2 protein interactions.J Biol Chem. 2001;276:29702-10.
62. Okamoto K,Li H,Jensen MR, et al.Cyclin G recruits PP2A to dephosphorylate Mdm2.Mol Cell. 2002;9:761-71.
63. Harper JW,Adami GR,Wei N,Keyomarsi K,Elledge SJ.The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.Cell. 1993;75:805-16.
64. Waga S,Hannon GJ,Beach D,Stillman B.The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA.Nature. 1994;369:574-8.
65. Adkins JN,Lumb KJ.Stoichiometry of cyclin A-cyclin-dependent kinase 2 inhibition by p21Cip1/Waf1.Biochemistry. 2000;39:13925-30.
66. Warner JR.The economics of ribosome biosynthesis in yeast.Trends Biochem Sci. 1999;24:437-40.
67. Schmidt EV.The role of c-myc in regulation of translation initiation.Oncogene. 2004;23:3217-21.
68. Dai MS,Lu H.Inhibition of MDM2-mediated p53 ubiquitination and degradation by ribosomal protein L5.J Biol Chem. 2004;279:44475-82.
69. Jin A,Itahana K,O'Keefe K,Zhang Y.Inhibition of HDM2 and activation of p53 by ribosomal protein L23.Mol Cell Biol. 2004;24:7669-80.
70. Tao W,Levine AJ.P19(ARF) stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2.Proc Natl Acad Sci U S A. 1999;96:6937-41.
71. Dai MS,Shi D,Jin Y, et al.Regulation of the MDM2-p53 pathway by ribosomal protein L11 involves a post-ubiquitination mechanism.J Biol Chem. 2006;281:24304-13.
72. Lindstrom MS,Jin A,Deisenroth C,White Wolf G,Zhang Y.Cancer-associated mutations in the MDM2 zinc finger domain disrupt ribosomal protein interaction and attenuate MDM2-induced p53 degradation.Mol Cell Biol. 2007;27:1056-68.
73. Gilkes DM,Chen L,Chen J.MDMX regulation of p53 response to ribosomal stress.EMBO J. 2006;25:5614-25.
74. Xiong X,Zhao Y,He H,Sun Y.Ribosomal protein S27-like and S27 interplay with p53-MDM2 axis as a target, a substrate and a regulator.Oncogene. 2011;30:1798-811.
75. Takagi M,Absalon MJ,McLure KG,Kastan MB.Regulation of p53 translation and induction after DNA damage by ribosomal protein L26 and nucleolin.Cell. 2005;123:49-63.
76. Ofir-Rosenfeld Y,Boggs K,Michael D,Kastan MB,Oren M.Mdm2 regulates p53 mRNA translation through inhibitory interactions with ribosomal protein L26.Mol Cell. 2008;32:180-9.
77. Horn HF,Vousden KH.Cooperation between the ribosomal proteins L5 and L11 in the p53 pathway.Oncogene. 2008;27:5774-84.
78. Cmejla R,Cmejlova J,Handrkova H, et al.Identification of mutations in the ribosomal protein L5 (RPL5) and ribosomal protein L11 (RPL11) genes in Czech patients with Diamond-Blackfan anemia.Hum Mutat. 2009;30:321-7.
79. Gazda HT,Sheen MR,Vlachos A, et al.Ribosomal protein L5 and L11 mutations are associated with cleft palate and abnormal thumbs in Diamond-Blackfan anemia patients.Am J Hum Genet. 2008;83:769-80.
80. Lai K,Amsterdam A,Farrington S,Bronson RT,Hopkins N,Lees JA.Many ribosomal protein mutations are associated with growth impairment and tumor predisposition in zebrafish.Dev Dyn. 2009;238:76-85.
81. Glaser R,Kiecolt-Glaser JK.Stress-induced immune dysfunction: implications for health.Nat Rev Immunol. 2005;5:243-51.
82. Lillberg K,Verkasalo PK,Kaprio J,Teppo L,Helenius H,Koskenvuo M.Stressful life events and risk of breast cancer in 10,808 women: a cohort study.Am J Epidemiol. 2003;157:415-23.
83. Stommel M,Given BA,Given CW.Depression and functional status as predictors of death among cancer patients.Cancer. 2002;94:2719-27.
84. Penninx BW,Guralnik JM,Pahor M, et al.Chronically depressed mood and cancer risk in older persons.J Natl Cancer Inst. 1998;90:1888-93.
85. Chida Y,Hamer M,Wardle J,Steptoe A.Do stress-related psychosocial factors contribute to cancer incidence and survival?.Nat Clin Pract Oncol. 2008;5:466-75.
86. Price MA,Tennant CC,Butow PN, et al.The role of psychosocial factors in the development of breast carcinoma: part II. Life event stressors, social support, defense style, and emotional control and their interactions.Cancer. 2001;91:686-97.
87. Feng Z,Liu L,Zhang C, et al.Chronic restraint stress attenuates p53 function and promotes tumorigenesis.Proc Natl Acad Sci U S A.:.
88. Hara MR,Kovacs JJ,Whalen EJ, et al.A stress response pathway regulates DNA damage through beta2-adrenoreceptors and beta-arrestin-1.Nature. 2011;477:349-53.
89. Beck IM,Vanden Berghe W,Vermeulen L,Yamamoto KR,Haegeman G,De Bosscher K.Crosstalk in inflammation: the interplay of glucocorticoid receptor-based mechanisms and kinases and phosphatases.Endocr Rev. 2009;30:830-82.
90. Revollo JR,Cidlowski JA.Mechanisms generating diversity in glucocorticoid receptor signaling.Ann N Y Acad Sci. 2009;1179:167-78.
91. Webster MK,Goya L,Ge Y,Maiyar AC,Firestone GL.Characterization of sgk, a novel member of the serine/threonine protein kinase gene family which is transcriptionally induced by glucocorticoids and serum.Mol Cell Biol. 1993;13:2031-40.
92. Amato R,D'Antona L,Porciatti G, et al.Sgk1 activates MDM2-dependent p53 degradation and affects cell proliferation, survival, and differentiation.J Mol Med (Berl). 2009;87:1221-39.
93. Oberbeck R.Catecholamines: physiological immunomodulators during health and illness.Curr Med Chem. 2006;13:1979-89.
94. Bartel DP.MicroRNAs: genomics, biogenesis, mechanism, and function.Cell. 2004;116:281-97.
95. Pillai RS,Bhattacharyya SN,Filipowicz W.Repression of protein synthesis by miRNAs: how many mechanisms?.Trends Cell Biol. 2007;17:118-26.
96. Plasterk RH.Micro RNAs in animal development.Cell. 2006;124:877-81.
97. Kent OA,Mendell JT.A small piece in the cancer puzzle: microRNAs as tumor suppressors and oncogenes.Oncogene. 2006;25:6188-96.
98. Caldas C,Brenton JD.Sizing up miRNAs as cancer genes.Nat Med. 2005;11:712-4.
99. Lu J,Getz G,Miska EA, et al.MicroRNA expression profiles classify human cancers.Nature. 2005;435:834-8.
100. Calin GA,Croce CM.MicroRNA signatures in human cancers.Nat Rev Cancer. 2006;6:857-66.
101. Zhang J,Sun Q,Zhang Z,Ge S,Han ZG,Chen WT.Loss of microRNA-143/145 disturbs cellular growth and apoptosis of human epithelial cancers by impairing the MDM2-p53 feedback loop.Oncogene. 2012;:.
102. Suh SS,Yoo JY,Nuovo GJ, et al.MicroRNAs/TP53 feedback circuitry in glioblastoma multiforme.Proc Natl Acad Sci U S A. 2012;109:5316-21.
103. Xiao J,Lin H,Luo X,Wang Z.miR-605 joins p53 network to form a p53:miR-605:Mdm2 positive feedback loop in response to stress.EMBO J. 2011;30:524-32.
104. Belyi VA,Ak P,Markert E, et al.The origins and evolution of the p53 family of genes.Cold Spring Harb Perspect Biol. 2010;2:a001198.
105. Lane DP,Cheok CF,Brown CJ,Madhumalar A,Ghadessy FJ,Verma C.The Mdm2 and p53 genes are conserved in the Arachnids.Cell Cycle. 2010;9:748-54.
106. Hu W,Zheng T,Wang J.Regulation of fertility by the p53 family members.Genes Cancer. 2011;2:420-30.
107. Morrison RS,Kinoshita Y,Johnson MD,Ghatan S,Ho JT,Garden G.Neuronal survival and cell death signaling pathways.Adv Exp Med Biol. 2002;513:41-86.
108. Gonfloni S,Di Tella L,Caldarola S, et al.Inhibition of the c-Abl-TAp63 pathway protects mouse oocytes from chemotherapy-induced death.Nat Med. 2009;15:1179-85.
109. Tomasini R,Tsuchihara K,Wilhelm M, et al.TAp73 knockout shows genomic instability with infertility and tumor suppressor functions.Genes Dev. 2008;22:2677-91.
110. Puzio-Kuter AM,Levine AJ.Stem cell biology meets p53.Nat Biotechnol. 2009;27:914-5.
111. Mendrysa SM,Ghassemifar S,Malek R.p53 in the CNS: perspectives on development, stem cells, and cancer.Genes Cancer. 2011;2:431-42.
112. Talos F,Abraham A,Vaseva AV, et al.p73 is an essential regulator of neural stem cell maintenance in embryonal and adult CNS neurogenesis.Cell Death Differ. 2010;17:1816-29.
113. Donehower LA.Using mice to examine p53 functions in cancer, aging, and longevity.Cold Spring Harb Perspect Biol. 2009;1:a001081.
114. Matoba S,Kang JG,Patino WD, et al.p53 regulates mitochondrial respiration.Science. 2006;312:1650-3.